COVID-19 in People Living with HIVRutgers University-New Brunswick
Rutgers expert explains why COVID-19 pandemic poses additional difficulties, risks to people with HIV
Even after heroic medical and societal efforts finally break the back of the current COVID-19 pandemic, the global sigh of relief may not last long. The chilling reality is that viral threats are growing more common. And they’re getting deadlier.
Researchers and clinicians can better understand the health risks facing people with HIV through comprehensive measures of alcohol use, including objective biomarkers, according to a new study in Alcoholism: Clinical and Experimental Research. Frequent or heavy alcohol use in people with HIV can affect HIV disease progression and comorbidities. Alcohol use disorder is a barrier to effectively managing HIV and contributes in multiple ways to poor health outcomes. These effects are not well understood, however, owing in part to the limitations of self-report tools (questionnaires) for measuring alcohol use. Researchers at Louisiana State University and Tulane University correlated self-reported alcohol use, measured by multiple questionnaires, with a biomarker of alcohol consumption in people with HIV. This study explores the implications of this multi-faceted approach for understanding the alcohol use of people with HIV and the related risk factors.
Global health scholars have issued a clarion call about the needless loss of life expected because of a foreseeable prospect of “slow and inadequate access to supplies” to control COVID-19 in sub-Saharan Africa. They say what is unfolding now is similar to when lifesaving diagnostics and treatments came to the region long after they were available elsewhere.
COVID-19 story ideas from Johns Hopkins.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.
The $6.6 million study will focus on how platelets function when they form clots in blood vessels and when they sense circulating pathogens, like viruses.
The advance has the potential to eliminate complications that arise from missing doses of life-saving medicines, according to the study published today in Nature Materials, a leading peer-reviewed biomedical research journal.
In a New England Journal of Medicine "Perspective" published today, Wafaa El-Sadr, MD, MPH, global director of ICAP at Columbia University Mailman School of Public Health, and Jessica Justman, MD, ICAP's senior technical director, and associate professor of epidemiology, urge a coordinated global effort in the face of the COVID-19 pandemic, with "countries around the world [taking] concrete steps to assist Africa in staying ahead of the curve, even as they confront their own epidemics."
People living with HIV/AIDS are at increased risk of depressive disorders. But all too often, these conditions go unrecognized or untreated, suggests a literature review in the May/June issue of Harvard Review of Psychiatry. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Appointment Enhances Efforts by the Institute to Improve Health of Communities Locally and Internationally
For years, curry lovers have sworn by the anti-inflammatory properties of turmeric, but its active compound, curcumin, has long frustrated scientists hoping to validate these claims with clinical studies.
When substance use disorder patients were tested for both HIV and hepatitis C virus at the same time and given the results within 20 minutes, they were far more likely a month later to indicate they had received results, compared with patients who were referred for testing services.
More than $3.7 million was awarded to Mahesh Mohan, DVM, MS, Ph.D., Professor at the Texas Biomedical Research Institute, and Chioma M. Okeoma, Ph.D., Associate Professor at Stony Brook University, to explore the link between cannabinoids (THC) and chronic intestinal inflammation in patients infected with the human immunodeficiency virus (HIV).
“We wanted to answer the question ‘How does HIV bounce back when treatment is stopped?'" said Dr. Florian Hladik.
José A. Bauermeister, PhD, MPH, Presidential Professor of Nursing, will be the next Chair of the University of Pennsylvania School of Nursing’s (Penn Nursing) Department of Family and Community Health, effective July 1, 2020.
A recent study from the George Washington University suggests that the innate protein AIBP restricts HIV-1 replications by targeting the lipid rafts the virus relies on.
Despite significant progress against HIV/AIDS, the nation’s capital is still battling an HIV epidemic with rates that are five times higher than the national average. A study published today in the journal Scientific Reports uses powerful next-generation sequencing technology to learn more about how the virus is spreading and developing drug resistance in the District of Columbia.
Summaries of recent Fred Hutch research studies, plus information on a press event at the upcoming AAAS annual meeting in Seattle.
In a study in Nature Medicine, researchers describe how injection of neutralizing antibodies are associated with enhanced T cell responses that specifically recognize HIV.
Data show that young adult women in the United States have high rates of sexually transmitted infections (STIs) that increase their risk of HIV. Though epidemiologic and behavioral factors for risk have been studied, we know very little about brain factors that may be linked to STI/ HIV sexual risk.
Overcoming HIV latency – activating HIV in CD4+ T cells that lay dormant – is a needed step toward a cure. Scientists at UNC-Chapel Hill, Emory University, and Qura Therapeutics – a partnership between UNC and ViiV Healthcare – showed it’s possible to drive HIV out of latency in two animal models.
A nanoparticle carrier system that could eliminate the need for bone marrow transplants, which are both expensive and difficult for patients to undergo. The University of Delaware's Emily Day, an assistant professor of biomedical engineering, is developing a platform that could treat stem cells directly without the need to remove them from the body.
A discovery by Florida State University College of Medicine researchers is expected to open the door for new and more potent treatment options for many of the more than 36 million people worldwide infected with the HIV virus and for others chronically ill with hepatitis B.
Providing multidisciplinary team consults for HIV patients while they are hospitalized to help address social and medical barriers reduces future infection rates and boosts participation in follow-up care, results from a study on how to reengage patients show.
A new study revealed that one dose of the HPV vaccine may prevent infection from the potential cancer-causing virus, according to research published in JAMA Network Open from The University of Texas Health Science Center at Houston (UTHealth).
New direct-acting antiviral (DAA) medications are highly effective in curing patients with hepatitis C virus (HCV). But these drugs carry a risk of interactions with antiretroviral therapy (ART) used to control HIV. An update on management of drug interactions in patients coinfected with HIV/HCV is presented in The Journal of the Association of Nurses in AIDS Care (JANAC). The official journal of the Association of Nurses in AIDS Care, JANAC is published in the Lippincott portfolio by Wolters Kluwer.
Pregnant women living with HIV don’t always receive antiretroviral medications recommended for use in pregnancy, according to a recent study published in Jama Network Open this week. Ann & Robert H. Lurie Children's Hospital of Chicago’s researchers collaborated in the multi-site Surveillance Monitoring for ART Toxicities (SMARTT) study of the Pediatric HIV/AIDS Cohort Study (PHACS) network.
The spending bill passed today is a welcome step forward. Allocations in the bill will strengthen public health and research efforts during the year ahead and will provide critical support for important goals. At the same time, the legislation in its final form also brings inadequate responses to current and urgent challenges with the potential for long-term and costly consequences.
UCLA Health experts weigh in on the most significant healthcare advances of the last ten years and what exciting developments we can look forward to in the decade ahead.
A drug purified and developed from the sap of a tree in the Amazon rainforest is now being studied for the treatment of chronic idiopathic diarrhea in non-HIV patients at The University of Texas Health Science Center at Houston (UTHealth) as part of a two-year pilot study.
Nearly three-fourths of young adults experiencing homelessness who are raped do not seek post-sexual assault medical care, missing an opportunity to greatly reduce their risk of contracting HIV, according to a survey led by The University of Texas Health Science Center at Houston (UTHealth).
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act passed by the House of Representatives today introduces critically needed and significant steps to reduce costs and improve access to life-saving therapies for conditions including HIV and hepatitis C. Importantly, the legislation also brings essential resources to combat antibiotic resistance, find and develop new infection fighting drugs and bring them to market. The balanced approach of this legislation will serve patients and public health.
A common first-line treatment approach for cryptococcal meningitis in low-income countries is being compromised by the emergence of drug resistance, new University of Liverpool research warns.
With a disproportionate number of black cisgender women in the U.S. becoming HIV positive, researchers are sharing critical health information through an atypical venue: the emergency room.
This World AIDS Day marks a promising and unprecedented point in a quest begun nearly four decades ago to end the global public health threat of HIV through science and solidarity. Increasingly, effective and essential technologies, medicines and measures to effectively treat the virus and prevent transmissions are finding their way to where they are needed most and are demonstrating that we have what is needed to end this pandemic. For the first time, the United States has developed a plan aiming to end the American epidemic. And in keeping with hard-earned knowledge as well as with the theme of this World AIDS Day, communities are at the center of ambitious responses. Still, this World AIDS Day finds progress stalled by policies and politics that threaten the momentum we have gathered.
The World Health Organization has set a goal of ending the AIDS epidemic by 2030.
Nearly 40 million people around the world are living with HIV, and experts believe about 20% do not know their status. In the U.S., more than 1 million people in the U.S. are living with HIV.
Some primates can carry SIV, a virus resembling HIV, lifelong and yet not develop AIDS. They are able to repair SIV damage to intestinal mucous tissues and avoid escape of gut bacteria and other events leading to immune system exhaustion. The findings offer clues for new HIV treatments
Penn Nursing has received a $100,000 grant from the Robert I. Jacobs Fund of the Philadelphia Foundation for HIV research. The grant supports an investigation, “Youth-driven Perspectives in HIV Biomedical Prevention and Cure Research,” led by José A. Bauermeister, PhD, MPH, Presidential Professor of Nursing.
A UC Davis study found that Lactobacillus plantarum bacteria rapidly repaired damaged gut lining (known as leaky gut) in monkeys infected with chronic simian immunodeficiency virus (SIV), an HIV-like virus. It linked chronically inflamed leaky gut to the loss of PPARα signaling and damage to mitochondria.
Rates of new anal cancer diagnoses and deaths related to human papillomavirus (HPV), the most common sexually transmitted infection, have increased dramatically over the last 15 years, according to researchers at The University of Texas Health Science Center at Houston (UTHealth). The results of their study will be published in the November issue of the Journal of the National Cancer Institute.
American Journal of Public Health article sees heightened dangers for Hispanics/Latinos, and an urgent need for enhanced public-health response.